Skip to Main Content

A five-year bull run in biotech has made scientists into millionaires, booked bonuses for bankers, and put venture capitalists into increasingly fancy cars. But in an industry prone to booms and busts, insiders with long memories aren’t getting too comfortable.

“I’m seeing a lot of investors making a lot of assumptions that may be accurate, but these assumptions are now becoming the consensus, and if anything goes wrong, there’s a long way down,” said Josh Schimmer, a biotech analyst at Evercore ISI.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

    • There have been ridiculous run ups for and valuations for companies like BGNE, ATRA, NKTR and countless others that are no where near approved/marketable products. In earlier times, this would have been considered a bubble.

Comments are closed.